H
Helio Tedesco-Silva
Researcher at Federal University of São Paulo
Publications - 195
Citations - 5204
Helio Tedesco-Silva is an academic researcher from Federal University of São Paulo. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 29, co-authored 159 publications receiving 4405 citations.
Papers
More filters
Journal ArticleDOI
Reduced exposure to calcineurin inhibitors in renal transplantation.
Henrik Ekberg,Helio Tedesco-Silva,Alper Demirbas,Stefan Vitko,Björn Nashan,A. Gurkan,Raimund Margreiter,Christian Hugo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +12 more
TL;DR: In this paper, the authors evaluated the efficacy and relative toxic effects of four immunosuppressive regimens: cyclosporine, mycophenolate mofetil, and corticosteroids.
Journal ArticleDOI
Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation
Henrik Ekberg,Corrado Bernasconi,Helio Tedesco-Silva,Stefan Vitko,Christian Hugo,Alper Demirbas,R Reyes Acevedo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +11 more
TL;DR: In the Symphony study, the largest ever prospective study in de novo kidney transplantation, over 3 years, daclizumab induction, MMF, steroids and low‐dose tacrolimus proved highly efficacious, without the negative effects on renal function commonly reported for standard CNI regimens
Journal ArticleDOI
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
Greg Knoll,Madzouka B. Kokolo,Ranjeeta Mallick,Andrew H. Beck,Chieny Buenaventura,Robin Ducharme,Rashad S. Barsoum,Corrado Bernasconi,Tom Blydt-Hansen,Henrik Ekberg,Claudia Rosso Felipe,John Firth,Lorenzo Gallon,M. Gelens,Denis Glotz,Jan Gossmann,Markus Guba,Ahmed Morsy,Rebekka Salgo,Earnst H Scheuermann,Helio Tedesco-Silva,Stefan Vitko,Christopher J.E. Watson,Dean Fergusson +23 more
TL;DR: Sirolimus was associated with a reduction in the risk of malignancy and non-melanoma skin cancer in transplant recipients and the use of this drug does not seem warranted for most patients with kidney transplant.
Journal ArticleDOI
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Helio Tedesco-Silva,Georges Mourad,Barry D. Kahan,Josep Grinyo Boira,Willem Weimar,Shamkant Mulgaonkar,Björn Nashan,Søren Madsen,Bernard Charpentier,Pascale Pellet,Yves Vanrenterghem +10 more
TL;DR: FTY720 at 2.5 mg was found to be as effective as MMF in combination with cyclosporine for the prevention of acute rejection after renal transplantation and was well tolerated and not associated with the side effects commonly observed with immunosuppressant therapies.
Journal ArticleDOI
Post-Transplant Anti-HLA Class II Antibodies as Risk Factor for Late Kidney Allograft Failure
Erika F. Campos,Helio Tedesco-Silva,Paula Goulart Pinheiro Machado,Marcello Franco,Jose O. Medina-Pestana,Maria Gerbase-DeLima +5 more
TL;DR: The presence of anti‐HLA class II antibody monitoring is a useful tool for the management of long‐term kidney recipients and conferred a risk for graft loss before a decline in renal function and increased the risk of graft failure in patients who already had a drop in graft function.